A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

BACKGROUND: Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience ...

HCM is a relatively common genetic cardiomyopathy that can be a challenge to diagnose, with about one in three patients misdiagnosed as having another cardiomyopathy. Genetic testing identifies a ...

Hypertrophic cardiomyopathy (HCM ... and the most appropriate investigations for persons suspected of having HCM. Treatment strategies for the disease and its complications are presented briefly.

Background: Symptoms are among the most important factors impacting quality of life (QOL) in hypertrophic cardiomyopathy (HCM) patients, and reflect a poor prognosis. Whether emotional stress can ...

Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of ...

an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is the generic name for AMVUTTRA ®, which is currently approved ...

The company is advancing its pipeline with a significant focus on developing treatments for hypertrophic cardiomyopathy and heart failure. In its third-quarter earnings report for 2024, Cytokinetics ...

Consult with your healthcare team so they can offer preventive care and appropriate treatments to help you better manage your ...